Abstract
Long COVID, also known as Post-acute COVID-19 Syndrome (PACS), is a chronic condition affecting individuals who have recovered from acute COVID-19. It is currently estimated that around 65 million people worldwide suffer from Long COVID. It is characterized by a range of symptoms, including fatigue, exertion intolerance, neurocognitive and sensory impairment, sleep disturbance, myalgia/arthralgia, and dysautonomia. Among them fatigue has emerged as a burdensome and pervasive issue, significantly impacting the quality of life and daily functioning of Long COVID patients. Alterations in the composition of the intestinal microbiota has been reported in COVID-19 patients. Dysbiosis persists even after several months of recovery from acute SARS-CoV-2 infection.
Based on this evidence, we carried out a phase 3, randomized, double-blind, placebo-controlled trial aimed at evaluating the efficacy of VSL#3®, a consortium of probiotic bacterial strains, in reducing fatigue and improving various aspects of patients’ well-being in patients with Long COVID syndrome.
Highlights
Patients suffering from Long-COVID manifest a variety of persistent symptoms impacting daily functioning;
Fatigue emerged as a burdensome and pervasive issue, significantly impacting the quality of life;
VSL#3® treatment significantly reduced the Chalder Fatigue Scale scores as compared to placebo
Chalder Fatigue Scale scores remained significantly reduced in the treatment group 4 weeks post intervention.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05874089
Funding Statement
This study was partially funded by Italian Ministry of Health, Current research IRCCS. This study received a financial non-conditioning grant by Actial Farmaceutica s.r.l. which also provided the probiotic product.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
approval by the ethics committee of IRCCS Fondazione Ca Granda Ospedale Maggiore Policlinico di Milano (number S62043).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
